Key result
SAFE-MCS evaluates Early Bird bleed monitoring safety during Impella-supported complex high-risk PCI.
Why the study?
High-risk PCI with mechanical circulatory support is associated with varying bleeding rates due to variable bleeding definitions, incomplete site-specific bleeding data, and variable patient populations.
Does surveillance with the Saranas Early Bird Bleed Monitoring System safely assess bleeding complications in patients undergoing complex high-risk PCI with Impella?
Does surveillance with the Saranas Early Bird Bleed Monitoring System safely assess bleeding complications in patients undergoing complex high-risk PCI with Impella?
Answers are grounded in this paper and cite their sources.
The SAFE-MCS study is designed to evaluate the safety and bleeding complications of complex high-risk PCI using Impella with surveillance by the Saranas Early Bird Bleed Monitoring System.
Background: High-risk percutaneous coronary intervention (PCI) with mechanical circulatory support (MCS) has been associated with varying rates of bleeding due to variable bleeding definitions, incomplete data relative to site-specific bleeding, and inclusion of variable patient populations. Study Design and Objectives: SAFE-MCS (NCT05077657) is a multicenter, single-arm, open-label study designed to evaluate the safety of complex high-risk PCI using Impella and surveillance with the Saranas Early Bird Bleed Monitoring System (EBBMS). The study aims to enroll 184 evaluable subjects at up to 15 US centers. The primary clinical end point is the incidence of access-site related BARC type III or V bleeding. Secondary clinical end points include the incidence of each of the Saranas EBBMS level 1, 2, and 3 indicators and the incidence of all BARC type III or V bleeding. Enrollment is anticipated to complete in September 2023 with no longitudinal follow-up. Conclusions: SAFE-MCS is the first study to exclusively assess bleeding complications in patients undergoing PCI with Impella with independent adjudication via a clinical end point committee and will gather meaningful real-world data using contemporary practice.
No takes yet. Share an insight, caveat, or question.
Généreux et al. (2023) studied Complex high-risk percutaneous coronary intervention (n=184). Saranas Early Bird Bleed Monitoring System (EBBMS) was evaluated on Incidence of access-site related BARC type III or V bleeding. The SAFE-MCS study is designed to enroll 184 patients to evaluate the safety of complex high-risk PCI using Impella and surveillance with the Saranas Early Bird Bleed Monitoring System.
Synapse has enriched 10 related papers. Consider them for comparative context: